We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
-0.89%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$5.06B
AUM Growth
-$417M
Cap. Flow
-$118M
Cap. Flow %
-2.33%
Top 10 Hldgs %
72.91%
Holding
44
New
1
Increased
20
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$51.9M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$47.7M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$32M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$30.3M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$19.8M

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$161M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$142M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$55.1M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$22M
5
UTHR icon
United Therapeutics
UTHR
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.68%
2 Miscellaneous 1.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DSGN icon
26
Design Therapeutics
DSGN
$765M
$31.1M 0.61%
2,222,222
– –
CBAY
27
DELISTED
Cymabay Therapeutics
CBAY
$30.4M 0.6%
10,300,000
– –
KYMR icon
28
Kymera Therapeutics
KYMR
$9.41B
$24.8M 0.49%
1,260,000
+443,500
+54% +$10.4M
WHWK
29
Whitehawk Therapeutics
WHWK
$233M
$22.5M 0.45%
1,829,402
– –
RNAM
30
DELISTED
Avidity Biosciences
RNAM
$18.9M 0.37%
1,300,000
– –
DICE
31
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$16.7M 0.33%
1,075,000
– –
MRNS
32
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$15.2M 0.3%
3,150,000
– –
NUVL
33
DELISTED
Nuvalent
NUVL
$14.2M 0.28%
1,049,471
– –
IOBT
34
DELISTED
IO Biotech
IOBT
$9.6M 0.19%
2,055,883
– –
AMRN
35
Amarin Corp
AMRN
$294M
$8.94M 0.18%
300,000
– –
TNGX icon
36
Tango Therapeutics
TNGX
$4.03B
$7.02M 0.14%
1,550,000
– –
FENC icon
37
Fennec Pharmaceuticals
FENC
$373M
$6.78M 0.13%
1,200,000
– –
RLAY icon
38
Relay Therapeutics
RLAY
$4.16B
$6.7M 0.13%
+400,000
New +$8.57M
AMTI
39
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$3M 0.06%
1,030,000
– –
GNCA
40
DELISTED
Genocea Biosciences, Inc.
GNCA
$86K ﹤0.01%
5,084,184
– –
ACAD icon
41
Acadia Pharmaceuticals
ACAD
$4.61B
– –
-2,275,000
Closed -$55.1M
ADVM
42
DELISTED
Adverum Biotechnologies
ADVM
– –
-695,000
Closed -$9.11M
AVDL
43
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-1,670,000
Closed -$11.4M
PRAX icon
44
Praxis Precision Medicines
PRAX
$8.74B
– –
-143,333
Closed -$22M
1
2

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Avoro Capital Advisors held 44 positions worth $5.06B, down 7.6% from $5.48B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Avoro Capital Advisors's Q2 2022 filing shows 1 new, 20 increased, 5 reduced and 4 closed positions. Its largest new stake was Relay Therapeutics: 400,000 shares worth $6.7M. The largest sale was State Street SPDR S&P Biotech ETF, an estimated $161M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier, followed by Miscellaneous.

  • Avoro Capital Advisors's largest Q2 2022 buy was Relay Therapeutics: 400,000 shares worth $6.7M.
  • Avoro Capital Advisors added most to Amicus Therapeutics in Q2 2022, an estimated $51.9M increase.
  • Avoro Capital Advisors's biggest Q2 2022 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $161M.
  • Avoro Capital Advisors fully exited Acadia Pharmaceuticals in Q2 2022, selling an estimated $55.1M.
  • Avoro Capital Advisors's ten largest holdings make up 73% of its $5.06B portfolio in Q2 2022.
  • Avoro Capital Advisors opened 1 new position and closed 4 in Q2 2022.
  • Avoro Capital Advisors's portfolio value fell 7.6% quarter-over-quarter to $5.06B.

Based on Avoro Capital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.